U.S. Markets open in 1 hr 12 mins

  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     

  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     

  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     

  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     

  • Crude Oil

    110.35
    +0.46 (+0.42%)
     

  • Gold

    1,845.10
    +3.90 (+0.21%)
     

  • Silver

    21.87
    -0.03 (-0.13%)
     

  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     

  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     

  • Vix

    29.43
    +0.08 (+0.27%)
     

  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     

  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     

  • BTC-USD

    29,087.67
    -388.11 (-1.32%)
     

  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     

  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     

  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     
WEF 2022:

Yahoo Finance is in Davos! Get the latest updates here

Global Large Volume Wearable Injectors Market Report 2021-2035: Emphasis on the Emergence of Patient-Centric, Convenient, Cost-Effective and User-Friendly Wearable Drug Delivery Solutions

·8 min read

DUBLIN, Jan. 10, 2022 /PRNewswire/ -- The "Large Volume Wearable Injectors Market by Type of Device, Usability, Therapeutic Area, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

The "Large Volume Wearable Injectors Market" report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next fifteen years.

It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2021-2035.

Over the last few years, the industry has seen the emergence of advanced drug delivery devices, such as wearable injectors, autoinjectors and pen injectors. These are the self-injection devices that have the capability of producing a sustained therapeutic effect, thereby improving patient adherence and efficacy of treatments. Such practices also allow reductions in costs and enable the optimal usage of healthcare resources.

The approval of novel drugs, specifically biologics that have high viscosity and cannot be administered in lower volume, has further led to an increased demand for advanced drug delivery devices. As a result, medical device industry has come up with several large volume wearable injectors suitable for the delivery of such molecules. These innovative injection systems offer numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, along with minimal or no risk of needlestick injuries.

The report features detailed transcripts of discussions held with the following individuals:

  • Mark Banister (CEO, Medipacs/RxActuator)

  • Michael Hooven (CEO, Enable Injections)

  • Jesper Roested (CEO, Subcuject)

  • Pieter Muntendam (former President and CEO, scPharmaceuticals)

  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)

  • Graham Reynolds (former Vice President and General Manager, Biologics, West Pharmaceutical Services)

  • (Vice President, Ypsomed)

  • Eric Chappel (R & D Project Manager, Debiotech)

  • Mindy Katz (Vice President, Marketing and Alliance Management, Sorrel Medical)

Key Questions Answered

  • Who are the leading large volume wearable device developers?

  • Which are the popular types of wearable devices available in this market?

  • What are the key challenges faced by stakeholders engaged in the development of large volume wearable injectors?

  • What types of partnership models are commonly being adopted by stakeholders in this industry?

  • Who are the key investors in this domain?

  • How has the intellectual property landscape of wearable injectors evolved over the years?

  • Which drug candidates are likely to be considered for administration via wearable injectors?

  • What factors are likely to influence the evolution of this market?

  • Which geographies are the most active in conducting clinical trials on large volume drug device combinations?

  • How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Large Volume Wearable Injectors For Non-Insulin Drugs: Current Market Landscape

5. Large Volume Drug Device Combinations: Current Market Landscape

6. Large Volume Wearable Injectors For Insulin Drugs: Current Market Landscape

7. Product Competitiveness Analysis

8. Large Volume Wearable Injectors: Company Profiles

9. Drug-Device Combinations: Tabulated Profiles

10. Partnerships And Collaborations

11. Key Acquisition Targets

12. Patent Analysis

13. Large Volume Wearable Injectors: Likely Drug Candidates

14. Clinical Trial Analysis

15. Funding And Investment Analysis

16. Case Study: Role Of Contract Manufacturing Organizations In Device Development Supply Chain

17. Regulatory And Reimbursement Landscape For Medical Devices

18. Market Sizing And Opportunity Analysis

19. SWOT Analysis

20. Executive Insights

21. Concluding Remarks

22. Appendix 1: Tabulated Data

23. Appendix 2: List Of Companies And Organizations

Companies Mentioned

  • 3E Bioventures

  • 3M

  • 5AM Ventures

  • Abbott

  • AbbVie

  • AbGenomics

  • Ablynx

  • Acceleron Pharma

  • ADC Therapeutics

  • Adrenomed

  • Aduro BioTech

  • Advaxis

  • Aeglea BioTherapeutics

  • Aesica Pharmaceuticals

  • Aetna

  • Affibody

  • Affimed

  • Agenus

  • AgonOx

  • Akesobio Australia

  • Alder BioPharmaceuticals

  • Alector

  • Alexion Pharmaceuticals

  • Alkahest

  • Alkermes

  • Allakos

  • Allergan

  • Allozyne

  • Alnylam Pharmaceuticals

  • AlphaCore Pharma

  • Altor BioScience

  • Ambrx

  • Amgen

  • Amicus Therapeutics

  • Amphivena Therapeutics

  • Amplyx Pharmaceuticals

  • AMSL Diabetes

  • Angiochem

  • Animas Corporation

  • Antaros Medical

  • Apellis Pharmaceuticals

  • Aptevo Therapeutics

  • Argenx

  • Argos Therapeutics

  • ArmaGen

  • ARMO BioSciences

  • Aronora

  • ArrowMark Partners

  • Arthurian Life Sciences

  • Asante Solutions

  • Ascensia Diabetes Care

  • Asklepion Pharmaceuticals

  • Astellas Pharma

  • AstraZeneca

  • Atridia

  • Axon Neuroscience

  • Baril

  • Basilea Pharmaceutica

  • Bastian Solutions

  • Baxter International

  • Bayer

  • Bayhill Therapeutics

  • Becton Dickinson

  • BeiGene

  • Beijing Dongfang Biotech

  • Bespak

  • Beta Bionics

  • Bigfoot Biomedicals

  • BioArctic

  • BIOCAD

  • Biogen

  • BioIntegrator

  • Bioject Medical Technologies

  • BioMarin Pharmaceutical

  • Bioniz Therapeutics

  • BioNTech

  • Bio-Path Holdings

  • Biotest Pharmaceuticals

  • Bio-Thera Solutions

  • Blackstone Life Sciences

  • BOCIG

  • Boehringer Ingelheim

  • Boston Pharmaceuticals

  • Calando Pharmaceuticals

  • Calibra Medical

  • Cam Med

  • CANbridge Life Sciences

  • Cancer Advances

  • Capital District Physicians' Health Plan

  • Cara Therapeutics

  • Cardiac Pacemakers

  • Cardiome Pharma

  • Care Innovations

  • Catalyst Biosciences

  • CCBio

  • Cecelia Health

  • Celgene

  • Celldex Therapeutics

  • CEL-SCI

  • CeQur

  • Chimerix

  • CHO Pharma

  • Chugai Pharmaceutical

  • Cincinnati Children's Hospital

  • CincyTech

  • Cintrifuse

  • Cleveland BioLabs

  • Cleveland Clinic

  • Cormorant Asset management

  • Conjupro Biotherapeutics

  • Consort Medical (Bespak Injectables)

  • ContraFect

  • ConvaTec

  • Cordant Group

  • Cormorant Asset Management

  • Cour Pharmaceutical Development

  • Credit Suisse Entrepreneur Capital

  • CStone Pharmaceuticals

  • CureTech

  • CytoDyn

  • Daikyo Seiko

  • Datwyler

  • Debiotech

  • Deka

  • Dekkun

  • Delta-Fly Pharma

  • Dendreon

  • Dexcom

  • Diabeloop

  • DreaMed Diabetes

  • Duke Clinical Research Institute

  • E3D Elcam Drug Delivery Devices

  • EG GILERO

  • Eisai

  • Eitan Medical

  • Eli Lilly

  • Elusys Therapeutics

  • EMD Serono

  • Emergent BioSolutions

  • Enable Injections

  • Endeavour Vision

  • Endocyte

  • EnGeneIC

  • EoFlow

  • EpicentRx

  • Eris Lifesciences

  • Eventide

  • EVER Pharma

  • Evidation Health

  • F2G

  • Fabrico

  • Farallon Capital

  • Federated Hermes Kaufmann Funds

  • Ferring Pharmaceuticals

  • FibroGen

  • Fitbit

  • Five Prime Therapeutics

  • Flex

  • Galaxy Biotech

  • Galena Biopharma

  • Genentech

  • GENERON

  • GeneScience Pharmaceuticals

  • Genexine

  • Genzyme

  • Gerresheimer

  • Gilead Sciences

  • Glenmark Pharmaceuticals

  • Gliknik

  • Glooko

  • GMS Capital

  • Guangzhou Cellprotek Pharmaceutical

  • HAL Allergy

  • Halozyme Therapeutics

  • Hanmi Pharmaceutical

  • Haselmeier

  • Hastings

  • Health Innovations

  • HealthPrize Technologies

  • Helsinn Healthcare

  • Huabo Biopharm

  • Huons

  • IBM Watson

  • Idea Bridge

  • ImClone Systems

  • Immatics Biotechnologies

  • Immune Response BioPharma

  • ImmunGene

  • Immunocore

  • ImmunoFrontier

  • ImmunoGen

  • Immunomedics

  • Immunotope

  • Immunovaccine

  • Implicit Bioscience

  • Incuron

  • Incyte

  • INKEF Capital

  • Innate Pharma

  • Innovent Biologics

  • Inovio Pharmaceuticals

  • Insight Product Development

  • Insulet

  • iNtRON Biotechnology

  • Invest-NL

  • IO Biotech

  • iOMEDICO AG

  • Ionis Pharmaceuticals

  • Ipsen

  • iSense CGM

  • ISU ABXIS

  • Janssen

  • Janus Capital

  • Janus Henderson

  • Jeffrey BrewerBryan Mazlish

  • Jerini

  • JHL Biotech

  • Jiangsu Hengrui Medicine

  • Jiangsu T-Mab Biopharma

  • Johnson & Johnson

  • Jounce Therapeutics

  • KaloBios Pharmaceuticals

  • Kingdon Capital

  • Kissei Pharmaceutical

  • Klue

  • Kreos Capital.

  • Kura Oncology

  • Kyowa Hakko Kirin

  • Labrys Biologics

  • LB investments

  • LEO Pharma

  • Levicept

  • Life Science Partner

  • LifeSci Venture Partners

  • Livongo

  • Loxo Oncology

  • LSP

  • Lundbeckfond Ventures

  • MabVax Therapeutics

  • MacroGenics

  • Madryn Asset Management

  • MedImmune

  • Medipacs

  • Medtronic

  • Medtrum Technologies

  • Menarini Diagnostics

  • Merck

  • Mereo BioPharma

  • Merrimack Pharmaceuticals

  • Mersana Therapeutics

  • Merus

  • Merz Pharma

  • Millennium Pharmaceuticals

  • MiNA Therapeutics

  • miRagen Therapeutics

  • Mitsubishi Tanabe Pharma Corporation

  • Mode AGC

  • Moderna Therapeutics

  • Molecular Partners

  • Molecular Templates

  • Molex

  • MolMed

  • Montagu Private Equity

  • MorphoSys

  • Morphotek

  • MOVI

  • MTD Micro Moldings

  • mySugr

  • NanoPass Technologies

  • NantBioScience

  • National Institutes of Health

  • Naurex

  • Navidea Biopharmaceuticals

  • Nemera

  • Neogenix Oncology

  • Neon Therapeutics

  • NeuroDerm

  • National Institute of Diabetes and Digestive and Kidney Diseases

  • Noble

  • Nordic Bioscience

  • Nordic Infucare

  • Northern Biologics

  • Novartis Pharmaceuticals

  • Novimmune

  • NOVO Engineering

  • Novo Nordisk

  • Nuokai Capital

  • Nutrino

  • NZMS Diabetes

  • OBI Pharma

  • Octapharma

  • Ohio Innovation Fund

  • Omeros

  • Oncology Venture

  • OncoMed Pharmaceuticals

  • OncoPep

  • Oncopeptides

  • Oncternal Therapeutics

  • Oncurious

  • Optimer Pharmaceuticals

  • OrbiMed

  • OSE Immunotherapeutics

  • Otsuka Pharmaceutical

  • Owen Mumford

  • Oxford Finance

  • Paion UK

  • Panacea Pharmaceuticals

  • Perceptive Advisors

  • PercuSense

  • Pfizer

  • PharmaMar

  • Pharmapack

  • PharmaSens

  • PhaseBio Pharmaceuticals

  • Phillips Medisize

  • Philogen

  • Phosplatin Therapeutics

  • Pierre Fabre

  • Pique Therapeutics

  • Polaris Group

  • Polyphor

  • Prescient Therapeutics

  • Prestige BioPharma

  • Promedior

  • Prometheus Laboratories

  • Protalix Biotherapeutics

  • Proven Process Medical Devices

  • Quadrant Capital Advisors

  • Quest PharmaTech

  • Quintessence Biosciences

  • RAUMEDIC

  • Raymond James

  • Recipharm

  • Recro Pharma

  • Regeneron Pharmaceuticals

  • REM Systems

  • REMD Biotherapeutics

  • Resolve Therapeutics

  • rEVO Biologics

  • Rhythm Pharmaceuticals

  • Roche

  • Roehr pharmaceuticals

  • R-Pharm

  • RTW

  • Rubin Medical

  • RxActuator

  • Sagentia

  • Samsung Bioepis

  • Samsung Electronics

  • Sandoz

  • Sanofi

  • Santarus

  • Saol Therapeutics

  • Savient Pharmaceuticals

  • Schroder and Bank

  • scPharmaceuticals

  • Seattle Genetics

  • Selecta Biosciences

  • Selexys Pharmaceuticals

  • Senseonics

  • Sensile Medical

  • Senvest Capital

  • Sequoia China

  • Serina Therapeutics

  • SFC Fluidics

  • Shire

  • SHL Medical

  • SMC

  • Smile Group

  • Smiths Medical

  • Soleus Capital Management

  • Sonceboz

  • SOOIL Development

  • SPARK Strategic Ideas

  • SQ Innovation

  • SteadyMed Therapeutics

  • Stealth BioTherapeutics

  • Stemline Therapeutics

  • Stevanato Group

  • Subcuject

  • Sumitomo Dainippon Pharma

  • Sun Pharma

  • Sunovion Pharmaceuticals

  • SVB Leerink

  • Swissfillon

  • SymBio Pharmaceuticals

  • Symphogen

  • Synectic

  • Synermore Biologics

  • Syntimmune

  • Syros Pharmaceuticals

  • TaiMed Biologics

  • Taiwan Liposome Company

  • Takeda Pharmaceutical

  • Tandem Diabetes Care

  • Tanvex BioPharma

  • Tarveda Therapeutics

  • Teva Pharmaceutical

  • TG Therapeutics

  • Theras Group

  • Tolero Pharmaceuticals

  • TRACON Pharmaceuticals

  • Translational Sciences

  • Triplejump

  • TRITECH BioMed

  • Turnstone Biologics

  • Tyndall National Institute

  • TypeZero Technologies

  • Unilife

  • Union Chimique Belge (UCB)

  • United BioPharma

  • United Therapeutics

  • Vaccinex

  • Vaccinogen

  • Valetritas

  • Valtronic

  • vasopharm BIOTECH

  • Verily Life Sciences

  • Vetter Pharma

  • VI Partners

  • ViCentra

  • ViiV Healthcare

  • Visionnaire Ventures

  • Visterra

  • Vivozon

  • Weibel CDS

  • Welldoc

  • West Pharmaceutical Services

  • Wipro

  • Wockhardt

  • Woodford Investment Management LLP

  • Xbiotech

  • Xencor

  • XOMA

  • Ypsomed

  • Zafgen

  • Zollner

  • Zuellig Pharma

For more information about this report visit https://www.researchandmarkets.com/r/7a0srm

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/global-large-volume-wearable-injectors-market-report-2021-2035-emphasis-on-the-emergence-of-patient-centric-convenient-cost-effective-and-user-friendly-wearable-drug-delivery-solutions-301457368.html

SOURCE Research and Markets

Recommended Stories

  • Alibaba Sales Beat as Consumption Holds Up During Lockdowns

    (Bloomberg) -- Alibaba Group Holding Ltd. reported a better-than-expected 9% rise in revenue after Chinese consumers turned to online malls for basic needs during Covid lockdowns across the country.Most Read from BloombergFed Saw Aggressive Hikes Providing Flexibility Later This YearBiden Demands US ‘Stand Up’ to Gun Makers After Texas AttackWhy So Few Big Rats Have Fled Putin’s ShipThese Are the Best — and Worst — Cities for Work-Life BalanceStocks Climb in Volatile Session After Fed Minutes: M

  • Why Shares of GameStop Are Surging Today

    Shares of the video game retailer GameStop (NYSE: GME) had popped nearly 26% as of 1:37 p.m. ET today as excitement over a potential short squeeze rose on social media. GameStop is the pioneer of the meme-stock movement that took 2021 by storm, so the stock is heavily susceptible to big random moves up and down. Today, it looks like interest in the stock on social media is building, as short interest has risen to the highest it's been in more than a year, according to analytics company Ortex.

  • Don’t get sucker-punched by capital gains taxes when you sell your home

    Longtime homeowners and those whose property value has skyrocketed could be in for a particularly nasty surprise. Here are some ways to reduce the tax bill.

  • Broadcom’s VMware Takeover Is Finally Official. Why the Stock Market Is Unenthused.

    Broadcom said Thursday it reached a deal to buy cloud-computing company VMware for about $61 billion. It would take second place behind Microsoft ( MSFT ) announced acquisition of Activision Blizzard ( ATVI ), which at nearly $70 billion would break records as one of the largest tech acquisitions. Broadcom (ticker: AVGO) stock was down 1.8% in premarket trading, and VMware (VMW) gained 1% to $121.71.

  • Nvidia stock falls after missing on second-quarter guidance

    Yahoo Finance's Jared Blikre examines Nvidia's Q1 earnings report and its stock movements in comparison to the rest of the semiconductor industry.

  • What to Do When a Bear Market Whacks Your 401(k)

    When the markets take a dive, your retirement savings could drop with them. Here is a four-step plan to beat the bear.

  • Costco set to report Q3 earnings on Thursday afternoon

    Yahoo Finance Live's Seana Smith looks at Costco shares ahead of the retailer's earnings report coming out tomorrow.

  • NYSE Vice Chair: ‘Markets have their ups and downs’

    Yahoo Finance Editor-at-Large Brian Sozzi is joined by NYSE Vice Chmn. & Chief Commercial Officer, John Tuttle at the 2022 World Economic Forum in Davos, Switzerland as they discuss the forum and the state of the market.

  • Dividend stocks have trounced the market this year. Here are 15 high-yield stocks expected to raise payouts the most through 2024

    DEEP DIVE The stock market, shocked by the Federal Reserve’s policy changes to fight inflation, has been gored this year, with growth and technology companies bearing the brunt of the biggest declines.

  • 3 Dow Stocks With 107% to 147% Upside, According to Wall Street

    Among the Dow Jones Industrial Average's 30 components are three that analysts believe could more than double over the next year.

  • J.P. Morgan Makes 2 Bottom-Fishing Bets for Over 90% Upside Potential

    Stock markets have been bearing the brunt of multiple headwinds in recent months. Persistently high inflation, slowing GDP growth, and a jobs market that, while expanding in absolute terms, is still down from pre-pandemic levels are feeding fears that we’re facing a round of ‘70’s-style stagflation. And these have combined with geopolitical factors – the Russia-Ukraine war, the resumption of severe lockdown policies in China – to ratchet up worries about recession in the near term. It’s a tradin

  • Royal Bank of Canada declares dividends

    Royal Bank of Canada (TSX: RY) (NYSE: RY) announced today that its board of directors has declared an increase to its quarterly common share dividend of eight cents or seven per cent, to $1.28 per share, payable on and after August 24, 2022, to common shareholders of record at the close of business on July 26, 2022.

  • Nvidia Stock Sank in After-Hours Trading Today -- Here's Why the Stock Could Be a Solid Buy

    The semiconductor titan is dealing with some near-term macroeconomic challenges, but its long-term future remains bright.

  • 2 “Strong Buy” Stocks Under $10 That Are Too Cheap to Ignore

    The current market conditions – the NASDAQ is down 28% year-to-date, and the S&P 500 is down 17% – offer bargain hunters a target-rich environment. Plenty of sound stocks have seen their prices decline, pulled down by the general market headwinds and the overall stock trend, to levels that have left them too cheap to ignore. At this level, investors can find the benefits of cheap stocks, like those under $10, which offer both learning opportunities and huge upside potential. However, in evaluati

  • Macy’s Posts an Earnings Beat and Raises Guidance. The Stock Spikes.

    Macy’s earns an adjusted profit of $1.08 a share in the quarter, well above the 39 cents in the year-ago period, on revenue of $5.35 billion.

  • Twitter Investors Deal a Big and Humiliating Blow to Musk

    Twitter did not provide any details about the proposed takeover offer from billionaire Elon Musk at its annual shareholder meeting.

  • CIBC Increases Dividends for the Quarter Ending July 31, 2022

    CIBC (TSX: CM) (NYSE: CM) announced today that its Board of Directors declared a dividend of $0.83 per share on common shares(1) for the quarter ending July 31, 2022, payable on July 28, 2022 to shareholders of record at the close of business on June 28, 2022.

  • After selling down Tesla position, Cathie Wood buys the dip

    Elon Musk-led electric-vehicle giant Tesla has slipped to third place among largest holdings in ARK Invest’s flagship exchange-traded fund, falling behind Roku and Zoom after the company lost its top spot last week.

  • The Trouble With Lithium

    (Bloomberg) -- Elon Musk wants to mine it, China is scouring Tibet for it, battery makers are crying out for it. Lithium, the wonder metal at the heart of the global shift to electric cars, is in a full-blown crisis. Demand has outstripped supply, pushing prices up almost 500% in a year and hindering the world’s most successful effort yet to halt global warming.Most Read from BloombergFed Saw Aggressive Hikes Providing Flexibility Later This YearBiden Demands US ‘Stand Up’ to Gun Makers After Te

  • Want $1 Million in Retirement? Invest $50,000 in These 3 Stocks and Wait a Decade

    The stock market could help you retire as a millionaire if you pick the right companies and hold them in your portfolio for a long time, as doing so will help you gain from the power of compounding and evolving trends in various industries. For instance, a $50,000 investment in Amazon a decade ago is worth about $500,000 now thanks to the stock's nearly 900% gains over the past decade, and that's after accounting for the steep drop in the e-commerce giant's stock price in recent months. Amazon, however, is not the only company that has generated solid returns for investors over the past decade.